Literature DB >> 8931499

Phospholipase A2 activity is selectively decreased in the striatum of chronic cocaine users.

B M Ross1, A Moszczynska, K Kalasinsky, S J Kish.   

Abstract

Dopamine-mediated stimulation of arachidonic acid metabolism, via activation of the phospholipid metabolizing enzyme phospholipase A2 (PLA2), has recently been implicated in dopamine neurotransmitter function. We examined the status of PLA2 in autopsied brain of 10 chronic users of cocaine, a dopamine reuptake inhibitor. PLA2 activity, assayed at pH 8.5 in the presence of Ca2+, was significantly (p < 0.01) decreased by 31% in the putamen of cocaine users (n = 10) compared with that in controls (n = 10), whereas activity was normal in the frontal and occipital cortices, subcortical white matter, and cerebellum. In contrast, calcium-independent PLA2 activity, assayed at pH 7.0, was normal in all brain regions examined. Our finding of altered PLA2 activity restricted to a region of high dopamine receptor density suggests that modulation of PLA2 may be involved in mediating some of the dopamine-related behavioral effects of cocaine and could conceivably contribute to dopamine-related processes in the normal brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931499     DOI: 10.1046/j.1471-4159.1996.67062620.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  2 in total

1.  Differential effects of cocaine exposure on the abundance of phospholipid species in rat brain and blood.

Authors:  Brian S Cummings; Sumitra Pati; Serap Sahin; Natalie E Scholpa; Prashant Monian; Paul M Trinquero; Jason K Clark; John J Wagner
Journal:  Drug Alcohol Depend       Date:  2015-04-22       Impact factor: 4.492

2.  Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Sujung J Yoon; In Kyoon Lyoo; Hengjun J Kim; Tae-Suk Kim; Young Hoon Sung; Namkug Kim; Scott E Lukas; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2009-12-30       Impact factor: 7.853

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.